An estimated 9.7 million infections and 50,800 deaths occur annually in the United States from bacterial and fungal pathogens according to data from CDC’s 2026 Antimicrobial Resistance Threats Report.
Released Oct. 27, the 2026 report identifies 19 bacterial and fungal threats classified as urgent, serious or concerning, along with six pathogens on a watch list because their full impact in the United States remains uncertain.
Of the estimated annual infections, more than 9.3 million involve drug-resistant pathogens, resulting in more than 39,000 deaths. The higher totals include Clostridioides difficile, which is not typically drug resistant but is included because antibiotic use and pathogen transmission contribute to both C. difficile infections and antimicrobial resistance.
The estimates are based on 2023 data and updated analytical methods. CDC cautioned against directly comparing the new findings with previous threat reports because of substantial changes in data sources and methodology for all pathogens except Candida auris.
In a statement responding to the report, Infectious Diseases Society of America President Wendy S. Armstrong, MD, FIDSA, described the findings as particularly concerning for clinicians treating patients with resistant infections.
“These numbers are alarming by any measure but are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience,” Dr. Armstrong said.
She also highlighted the implications of drug-resistant infections for medical procedures, including cancer chemotherapy, organ transplantation and joint replacement surgery. "Drug-resistant infections prolong hospital stays, drive up health care costs and make it increasingly difficult—and sometimes impossible—for doctors to safely provide care like cancer chemotherapy, organ transplants, hip and knee replacements and other medical care and surgeries," she said.
IDSA calls for federal action
Alongside the updated CDC estimates, IDSA called on Congress to pass the bipartisan PASTEUR Act, legislation intended to encourage the development of new antimicrobial drugs and support antimicrobial stewardship.
“It is imperative that Congress pass the bipartisan PASTEUR Act to drive the development of the lifesaving novel antimicrobial drugs that are needed to treat resistant infections and to support antimicrobial stewardship programs to ensure that patients in all communities receive optimal care that protects the effectiveness of our precious antimicrobial drugs,” Dr. Armstrong said.
Four pathogens classified as urgent threats
CDC identified four pathogens as urgent threats requiring immediate public health attention:
Candida auris
Carbapenem-resistant Acinetobacter
Carbapenem-resistant Enterobacterales
Drug-resistant Neisseria gonorrhoeae
These pathogens present different clinical and public health challenges, ranging from infections associated with health care exposure to sexually transmitted infections with increasingly limited treatment options.
The report also highlights the continued emergence of C. auris, a fungal pathogen that can spread in health care facilities and cause severe infections. CDC previously documented a nearly fivefold increase in reported clinical cases between 2019 and 2022.
C. difficile moves to serious threat category
One notable change in the 2026 report is the reclassification of C. difficile from an urgent to a serious threat.
CDC attributed the change partly to improvements in infection prevention, particularly in health care settings, where the agency has documented declines in infections since 2011.
Despite the revised classification, C. difficile continues to cause substantial numbers of infections and deaths, as well as health care costs. It remains an important cause of health care-associated infections, according to CDC.
The updated estimates also account for infections among patients outside hospital settings, providing a broader assessment of the pathogen’s impact.
New pathogens added to surveillance categories
The report adds drug-resistant Neisseria meningitidis to the serious threat category.
Three pathogens were also added to CDC’s watch list: drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria. The watch list now contains six pathogens, including azole-resistant Aspergillus fumigatus, drug-resistant Bordetella pertussis and drug-resistant Mycoplasma genitalium.
CDC evaluates threats using factors that include clinical and economic impact, infection incidence, projected changes over five years, transmissibility, preventability and the availability of effective treatments.
Health care-associated infections
According to CDC, seven bacterial threats commonly associated with health care caused more than 42,000 deaths in 2023 and accounted for nearly $12 billion in health care costs.
The report also highlights ongoing challenges in preventing antimicrobial-resistant infections in hospitals. Previous CDC analyses found that hospital-onset infections involving six drug-resistant bacterial pathogens increased by 20% during the COVID-19 pandemic compared with the prepandemic period. Although rates declined after peaking in 2021, they remained above prepandemic levels in 2022.
The 2026 report also expands the scope of estimates for drug-resistant group A Streptococcus and clindamycin-resistant group B Streptococcus to include noninvasive as well as invasive infections.